People with type 1 diabetes who are “hyperglycemia aversive” reduce their hyperglycemia exposure at the cost of increased hypoglycemia and, potentially, reduced hypoglycemia awareness, research suggests.
COVID-19 restrictions do not significantly impact glycated hemoglobin levels in individuals with type 2 diabetes, but those with poor psychologic wellbeing may experience worsening glycemic control, suggest findings from an Italian study.
Findings from a US randomized controlled trial suggest that add-on treatment with the SGLT2 inhibitor dapagliflozin reduces levels of some vasoconstrictors and increases some vasodilators in people with type 2 diabetes.
Flash glucose monitoring is associated with small but sustained improvements in glycemic control and a reduction in severe hypoglycemia relative to self-monitoring of blood glucose in type 1 diabetes, observational data show.
Older people with type 2 diabetes who initiate treatment with long-acting insulin analogs have a lower risk for severe hypoglycemia than those using neutral protamine Hagedorn insulin, real-world study findings suggest.